retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Retatrutide for Lab-Grade Canadian Researchers

If you are planning a pregnancy, youll usually be advised to stop these medicines some time before conception and switch to treatments known to be safe in pregnancy, such as insulin

The sheer number of compounds in development means that within five years, the weight management medication landscape will look dramatically different than it does today

Building and rebalancing the gut microbiome is a process, not an overnight event

Appetite suppression vs weight loss vs blood sugar: three different timelines One of the biggest sources of confusion is that GLP-1 medications produce multiple effects, and each one operates on its own timeline

Statins and the risk of acute pancreatitis: a population-based case-control study